All entries for: Akebia Therapeutics Inc

November 10, 2025

Akebia Therapeutics Inc

Negative Outlook

Cambridge, MA
51-200 employees

The implications and consequences of these actions and subsequent actions by the Trump Administration to compel an MFN regulatory pricing requirement in the U.S. continue to remain unclear and uncertain and could ultimately result in litigation. However, if an MFN regulatory pricing requirement is implemented in the U.S., it could have an adverse effect on our business.

Scroll to Top